Amidst tremendous demand traction and prevalence of diverse market participants at regional and international levels, aspiring participants in global preimplantation genetic diagnostics (PGD) market are vigorously upgrading their genetic testing technology for superlative clinical outcome, aimed at improved end-user experience and healthcare efficiency. At the backdrop of urbanization and growing women workforce, childbearing has taken a backseat, thereby, significantly elevating the demographics of late pregnancies.
However the implications of delayed pregnancies certainly entail substantial chances of birth complications and ailments. Besides risks of birth defects, infertility is yet another growing concern that necessitate adoption of preimplantation genetic diagnosis. To offset probabilities of genetic diseases in off springs, patients demonstrate extensive reliance towards such diagnostic measures, thus thrusting preimplantation genetic diagnosis market towards flourishing growth in the coming years.
Preimplantation genetic diagnosis (PGD) is essentially profiling the embryos and oocytes prior to their implantation and fertilization respectively. The technique is massively adopted in in vitro fertilization which is employed for detecting critical genetic conditions and deformities. The expanse of detecting disease probability is rather large in preimplantation genetic diagnosis space such as various genetically acquired diseases, besides psychological abnormalities and Down’s Syndrome are just to name a few. Besides conventional PGD techniques, integration of FISH and comparative genomic hybridization (CGH) tests have farther entailed massive competitive advantage allowing PGD market to register concomitant growth in subsequent times.
Browse the full Preimplantation Genetic Diagnosis Market Report: https://www.mrrse.com/asia-preimplantation-genetic-diagnosis-market
Diagnosis of Chromosomal Abnormalities Entails Promising Growth
Amongst a host of PGD tests available, diagnosis for aneuploidy screening which essentially is detection of chromosome abnormalities has been massively influenced by micro-array based testing mechanics that enables precise analysis of 24 chromosomes in a single test. Adoption of single-nucleotide polymorphism microarrays sheds reliable information on potential chromosome alterations for improved IVF results. Factors as such are pegged to translate enormous growth potential in preimplantation genetic diagnosis (PGD) market in forthcoming years.
Illumina Grannts Commercialization Rights of its PGD Solutions to Vitrolife
The competition spectrum of preimplantation diagnosis market is characterized by big ticket market participants who are relying on diverse organic and inorganic growth strategies to sustain lead amidst staggering competition. In a recent development, notable IVF solutions provider Vitrolife AB has entered into a strategic collaboration agreement with Illumina, best known for its genetic variation diagnosis system. UNder the terms of the agreement, Vitrolife has been granted with exclusive commercialization rights of Illumina’s revolutionary preimplantation genetic testing solutions for IVF across the Americas and EMEA regional hubs. This development is expected to entail long term growth potential, encouraging greater adoption of IVF friendly PGD services.